SYMED LABS LIMITED v. GLENMARK PHARMACEUTICALS INC., USA
2:15-cv-08306
Overview
Parties
Defendant
GLENMARK PHARMACEUTICALS INC., USA Operating Company
Represented By
0 Attorneys ListedPlaintiff
SYMED LABS LIMITED NPE (University / Research)
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. New Jersey (njd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7732597
Crystalline form of linezolid
|
Filed: 2007-09-26
Issued: 2010-06-08
|
Expired (Term Ended)
Expires: 2024-02-22
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
10
Dispositive
0
Granted
4
Denied
0
Pending / Review
3
Motions by Category
Key Dispositive Motions & Rulings